Electronic Prior Authorization: A Guide to Top 5 ePA Platforms

Prior Authorization (PA) is a widely used utilization-management tool in U.S. healthcare, meant to ensure that high-cost or high-risk treatments are medically appropriate. Traditionally, PA has been a time-consuming, paper-based process involving phone calls and faxes. Studies have documented the burden: on average, physician practices complete ~29.1 PAs per physician per week, requiring nearly two full workdays each week and costing each physician $2,000–14,000 annually (^[1]) (^[2]). These delays frustrate providers and patients: clinicians often learn of PA requirements only after a pharmacy rejects the prescription, creating “brick wall” delays (^[3]) (^[4]).

Electronic Prior Authorization (ePA) systems aim to automate and streamline this workflow by integrating PA requests into the clinical workflow. Leading solutions (e.g. CoverMyMeds, Surescripts’ CompletEPA, OptimizeRx, DrFirst, Availity) provide patient-specific eligibility and formulary checks, in-terminal submissions of PA forms, and automated receipt of payer decisions. According to industry reports, ePA can dramatically shorten turnaround times: one CoverMyMeds report found 62% of ePA requests resolved in under 2 hours (versus 0% via fax/phone) (^[5]), and dispense rates rise by ~80% with ePA’s quicker turnaround (^[5]). Surescripts similarly reports average PA approvals in <4 minutes electronically, saving over two days of patient wait time on average (^[6]) (^[2]).

However, despite the promise, adoption is still growing and outcomes are mixed. By 2019 only about 47.5% of U.S. PA requests occurred via ePA systems (^[7]), though adoption has accelerated considerably since then — by 2025, roughly 65% of Epic organizations used ePA, and ePA transaction volumes on Epic systems nearly doubled from 16 million per quarter in 2023 to 29 million per quarter in early 2025 (^[8]). A recent large observational study at Sutter Health found that among medications requiring PA, only 1.9% of orders were routed through ePA, and ePA implementation actually did not improve medication fill rates or primary adherence (^[9]) (^[10]). Similarly, a 2022 provider survey found ePA users saw faster approval decisions but no reduction in total time spent on PA tasks, likely because ePA adoption is partial and benefits information is not always fully integrated (^[11]). Recent case analyses also highlight pitfalls: one leading health system found that over 94% of its prospective ePA alerts for albuterol inhalers were false positives (because benefit data are often outdated), creating unnecessary work (^[12]).

This report examines the Top 5 ePA platforms – namely CoverMyMeds (McKesson), Surescripts (CompletEPA), OptimizeRx, DrFirst, and Availity – along with related EHR-integrated and payer-based solutions. For each, we detail its history, technology, network reach, and performance claims. We synthesize data from industry scorecards, peer-reviewed studies, and stakeholder surveys to evaluate ePA’s impact on workflows, costs, and patient access. We also discuss multi-stakeholder perspectives (providers, pharmacists, payers, life-sciences) and emerging regulations. Finally, we analyze future directions: new interoperability standards (like HL7® FHIR PriorAuth APIs), regulatory mandates (CMS final rule CMS-0057-F requiring payer APIs by 2027 (^[13]) (^[14])), and next-generation data tools (real-time benefits, AI-driven automation). Throughout, we provide extensive data, case examples, and citations.

The evidence suggests that ePA technologies can markedly accelerate specific parts of the PA process and improve prescription fulfillment, but they do not yet eliminate the administrative burden. Widespread benefits will likely rely on universal standards (to avoid fragmented systems), full provider integration, and complementary solutions (real-time benefit checks, patient support hubs). The CMS-0057-F rule's operational provisions took effect January 1, 2026, with FHIR API requirements following by January 1, 2027, further pushing the ecosystem toward interoperable, point-of-care ePA exchanges (^[13]) (^[14]). In sum, ePA platforms represent a promising advance, but realizing their full potential requires both broader adoption and smarter integration of clinical data.

The Burden of Manual Prior Authorization

Prior authorization is a utilization-management policy whereby insurers require prescribers to obtain approval before certain medications or services will be covered. Its intent is to ensure appropriate use of high-cost or high-risk therapies. However, a large body of evidence documents that manual PA is inefficient and engrossing. In one physician survey, practices reported completing an average of 29.1 prior authorizations per physician per week, consuming almost two full business days of work (^[1]). In other words, over 40 hours per year per physician is spent on PA paperwork. The manual process typically relies on faxes and phone calls: for example, 90% of PA requests require fax or phone (^[2]). A Health Affairs report noted that physicians spend more time on PA than on any other payer interaction (roughly 8 hours per week), and the aggregate cost per physician ranges from $2,000 to $14,000 per year (^[2]).

Patients suffer delays and uncertainty. A 2023 commentary in NEJM observes that clinicians often discover PA requirements only after a prescription is rejected at the pharmacy, leaving patients waiting at the pickup counter (^[3]). This frustration has real consequences. Prior authorization delays lead to medication nonadherence: one study estimated lack of timely PA contributes to ~20% of prescriptions going unfilled when needed (^[5]) (^[15]). Clinicians themselves report that PA processes impede efficiency and detract from patient care. For these reasons, professional bodies (e.g. </current_article_content>the American Medical Association) have vigorously advocated for PA reform and automation, calling for “right-sizing” PA programs and implementing electronic solutions (^[1]) (^[16]).

Emergence of Electronic Prior Authorization (ePA)

Electronic Prior Authorization (ePA) refers to digital systems that enable submission, tracking, and adjudication of PA requests within an electronic workflow. Around the 2010s, a convergence of factors spurred interest in ePA: the digitization of prescribing, the development of standards, and high-profile provider frustration with manual PA. Two major networks emerged:

• CoverMyMeds (founded 2008) developed a web/EHR-embedded platform to automate drug PA. Over time it built extensive connectivity, eventually claiming integration with over 500 EHRs, 47,000 pharmacies, and payers covering 94% of U.S. prescription volume (^[17]) (^[18]). (CoverMyMeds was acquired by McKesson in 2017 for $1.1 billion and remains a wholly owned McKesson subsidiary.)
• Surescripts‘ CompletEPA (launched 2014) offered an end-to-end ePA service built on the national e-prescribing network. By 2014 it connected physician EHRs to four major PBMs (e.g. CVS Caremark, Express Scripts), representing access for 210 million covered lives (^[19]). Surescripts reports that its ePA platform can eliminate roughly 10 minutes of active work per PA and deliver decisions in under 4 minutes on average (^[20]) (^[2]).

These vendors leveraged the NCPDP SCRIPT standard (released in 2013-2017 iterations, with a newer v2023011 version required by 2028) which introduced structured PA request and response messages, enabling automation between providers’ EHRs and payers’ systems. Adoption has grown substantially: CoverMyMeds’ 2020 industry scorecard noted that ~47.5% of PAs were handled electronically (^[7]), and by 2025, roughly 65% of Epic organizations had adopted ePA. Surescripts reported exchanging 30.5 billion health intelligence transactions in 2025 (a 12.3% increase over 2024), and 84% of prescribers now use EHRs equipped with Surescripts Electronic Prior Authorization (^[21]). CoverMyMeds estimated it handles 90% of the ePA transactions in the market (^[22]), reflecting its dominant network.

From the patient’s perspective, ePA is often paired with real-time benefit checks at prescribing time to preemptively highlight costs or PA requirements. New systems increasingly integrate both functions, so that prescribers can know immediately if a PA will be needed, initiate it in the exam room, and receive status updates digitally. These integrated workflows aim to “resolve PA at the point of care” and eliminate pharmacy bottlenecks (^[4]) (^[23]).

Policy and Regulatory Drivers

Federal policy has begun to push ePA adoption. In 2018, the SUPPORT Act mandated that Medicare Part D insurers support e-prescribing systems capable of transmitting PA requests (initial enforcement was delayed until 2022) (^[15]). More recently, the 21st Century Cures Act and related rules emphasize interoperability. In December 2022 the Centers for Medicare & Medicaid Services (CMS) proposed the CMS-0057 rule (“Advancing Interoperability/Improving PA Processes”), and in January 2024 they finalized it (^[24]) (^[13]). The final rule requires Medicare Advantage and Medicaid payers to implement FHIR-based Prior Authorization APIs by January 1, 2027, to allow electronic PA submissions and decision retrieval. Crucially, operational provisions took effect January 1, 2026: payers must now issue PA determinations within 72 hours for expedited requests and 7 calendar days for standard requests (shortened from the previous 14-day window), and must begin publicly reporting PA metrics (with the first reports for calendar year 2025 due by March 31, 2026) (^[25]). The rule also adds an “ePA” measure to the Quality Payment Program (MIPS) starting in calendar year 2027, under which clinicians will attest whether they have requested PA electronically (^[14]) (^[13]). In mid-2025, more than 50 major health insurers made voluntary commitments to simplify PA starting in 2026, including reducing unnecessary PA requirements, honoring 90-day treatment transitions, and expanding real-time electronic responses (^[26]). In short, ePA has moved from optional to effectively required for providers and insurers.

In summary, the landscape is shifting from paper to digital. Numerous ePA platforms have been developed and adopted, but research and stakeholder reports show mixed results. This report analyzes the leading ePA solutions and their impact, drawing on academic studies, industry data, and regulatory analyses to provide a deep, evidence-based picture of where ePA stands today, and where it is heading.

The ePA market is served by several major platforms. We focus here on the most prominent: CoverMyMeds, Surescripts CompletEPA, OptimizeRx, DrFirst, and Availity. (Other solutions exist—such as EHR-embedded modules from Epic/Cerner or PBM systems like OptumRx—but the listed platforms represent the highest-profile, widely marketed products.)

Platform	Description & Key Features	Primary Users/Integrations	Parent Company/Status
CoverMyMeds	Launched 2008, now the largest ePA network. Provides a cloud/EHR-integrated portal for submitting medication PA requests. Key features include real-time benefit info (RxBenefit Clarity®) and tracking. According to the company, it captures ~90% of all U.S. ePA volume ([22]). Covers all drug classes and payers, routing requests to payers by electronic submission or, if needed, by automated fax. Complete digital audit trail for providers and pharmacies.	Widely integrated: works with 500+ EHR systems (Epic, Oracle Health/Cerner, NextGen, etc.) and 50,000+ pharmacies, with payers representing 94% of U.S. prescription volume ([18]) ([17]). Accessible to 700,000 prescribers via EHR. Also used by specialty pharmacies and life-science companies for patient access programs.	Acquired by McKesson in 2017 for $1.1 billion. Continues as a wholly owned McKesson subsidiary. In 2025, CoverMyMeds acquired RxLightning and FastAuth to expand specialty medication and automated PA capabilities ([27]).
Surescripts (CompletEPA)	Built on the national e-prescribing network. CompletEPA was rolled out in 2014–2015 to provide end-to-end ePA functionality. Features include point-of-care PA initiation and submission within the EHR, plus receipt of payer response (approval/denial) directly in the workflow. Also offers a web portal for providers whose EHRs lack integration. Surescripts highlights metrics like “10 minutes saved per PA” and ”<4 minutes to get a determination” on average ([20]). In 2025, Surescripts launched Touchless Prior Authorization, which automates PA end-to-end with a median approval time of just 22 seconds, now reaching 76,000+ prescribers across 70+ medications ([28]).	Integrated with EHR vendors (Allscripts, Athenahealth, etc.) and pharmacies. Connected to major PBMs like Express Scripts and CVS Caremark; 84% of prescribers now use EHRs equipped with Surescripts ePA ([21]). Originally covering 210 million lives (70% of market) at launch; network has expanded significantly since ([29]).	Surescripts LP (a nonprofit joint venture of major pharmacy chains and health plans). Longtime operator of the e-prescribing network.
OptimizeRx	A digital point-of-care platform focusing on pharmaceutical patient access. In 2021, launched its Therapy Initiation Workflow which consolidates benefits enrollment, verification, PA submission, and patient support (onsite hubs) into one interface ([30]). Geared especially to specialty medications requiring complex workflows. Marketed as “digitizing pharma access solutions” with real-time data.	Interfaces with over 700,000 providers (across EHRs and portals) and connects them to pharmacies, payer systems, and manufacturer hubs ([31]). Provides push messages and alerts to doctors (e.g. drug-cost alerts) as well as PA triggers. Strong presence in specialty therapy areas via life-science partnerships.	Public company (NASDAQ: OPRX). Remains independent; reported full-year 2025 revenue and issued 2026 guidance of $109–114 million.
DrFirst (Patient Advisor ePA+)	EHR-embedded solution offered by DrFirst, a clinical connectivity vendor. Uses a hybrid approach: under the hood it leverages the CoverMyMeds platform to submit PA requests, and integrates Surescripts’ CompletEPA for certain payers ([23]). Promises “end-to-end automation” of PA for specialty drugs, with workflow alerts and patient-specific data. Claims to reduce manual work by ~70% through automated form population and eligibility checks ([32]).	Integrated directly into DrFirst’s own EHR products (e.g. EHRs that license DrFirst). Also used by ambulatory EHRs that have partnered with DrFirst. Thus reaches participating physician offices.	DrFirst (health IT vendor). Actively enhances its ePA with AI and real-time benefit features (per company blogs).
Availity End-to-End Authorizations	A payer-provider clearinghouse solution that now includes AI-assisted ePA workflows. Ensures CMS compliance and offers an integrated UI for submitting PAs (pharmacy or medical) across various payers. Also provides analytics on authorization metrics. Availity's AuthAI recommendation engine renders PA recommendations in under 90 seconds, and the platform claims to automate up to 80% of the utilization management workload ([33]). In January 2026, Availity partnered with Abridge to integrate conversational AI into real-time PA workflows during clinical encounters ([34]).	Used by provider offices, hospitals, and health plans that subscribe to the Availity Exchange. Connects to many payers’ systems (including Medicaid, Medicare Advantage, and commercial). Allows multiple providers (hospitals, clinics) to cross-search for PA status.	Availity LLC (independent operator under Surescripts/AmeriHealth joint venture, formerly DHX).

Each of these platforms strives to embed PA into clinical workflows. For example, CoverMyMeds offers an “EasyButton” for providers to click within the EHR and launch a PA request (^[35]). Surescripts has certified EHR vendors where CompletEPA is integrated, so a PA decision appears like any other prescription response. OptimizeRx and DrFirst focus initially on physician specialty portals and then expand to full EHR integration. Availity, traditionally a clearinghouse, serves as a neutral hub making provider-payer communication uni­fied.

Table 1 (above) compares key attributes of each system. In practice, many provider organizations use multiple vendors to cover all payers. As one industry leader noted, “Surescripts has a piece of the market, and CoverMyMeds has some kind of connection to every payer in the country… we have to have multiple sources available” (^[36]). This fragmentation means that achieving seamless ePA still requires significant implementation work for health systems.

Platform Highlights and Data

CoverMyMeds

CoverMyMeds is widely regarded as the most ubiquitous ePA network. Its data reports claim that the platform has facilitated over 200 million medication access events (refills, PA approvals, etc.) to date (^[37]). In CoverMyMeds’ 2019 national adoption scorecard, 62% of ePA requests received a determination in under 2 hours (^[5]) – a speed that traditional phone/fax could never match. The same report linked ePA to an 80% higher dispense rate and 3% higher chance that a ready prescription is actually picked up (^[5]). In practical terms, CoverMyMeds data suggest patients get their medication faster and with fewer drop-offs when PAs are handled electronically.

According to CoverMyMeds, 70,000+ providers and 47,000 pharmacies are “activated” on its network (^[18]). A 2017 McKesson press release (when McKesson first purchased CoverMyMeds) stated that by then CoverMyMeds was streamlining PA across 47,000 pharmacies and 700,000 prescribers (^[18]). More recent marketing materials emphasize their integration with 94% of prescription volume (^[17]).

CoverMyMeds offers advanced features:

• Clinical criteria checks: It guides providers through payer-specific documentation requirements.
• Real-time benefit check integration: Its RxBenefit Clarity™ system can display patient copays and coverage details alongside PA results (^[5]).
• Mobile options: Pharmacists and reps can initiate a PA request from any computer or phone (Dropbox-style web portal plus some mobile apps).
• Pharmacy connectivity: Pharmacies (chains and independents) submit PAs back to prescribers via CoverMyMeds, increasing capture of needed requests.

However, CoverMyMeds is not a fee service for providers: it is funded by pharma and PBMs. Providers and pharmacies use it at no charge, which aided its rapid network growth. Its neutrality (not part of an EHR or payer) enables it to bridge disparate systems.

In 2025, CoverMyMeds further expanded its capabilities by acquiring RxLightning (a digital-first specialty medication enrollment platform) and FastAuth (an automated end-to-end patient access software). These acquisitions bolster CoverMyMeds' ability to streamline specialty medication enrollment and automate complex PA workflows, reducing administrative errors from paper forms and faxes (^[27]).

Surescripts CompletEPA

As the incumbent national prescribing network, Surescripts expanded into ePA with CompletEPA. It touts the ability to eliminate up to 10 minutes of work per PA request (^[20]) and to dramatically speed decision times. In controlled settings, the network achieves <4-minute turnaround once all data are submitted (^[6]). Surescripts’ 2014 press release highlighted that 90% of PAs were still done by fax and that automation could save $100-$300 of administrative cost per PA (^[2]). It positioned CompletEPA as the solution, connecting to major PBMs covering 210 million lives (70% of the market) (^[29]).

Surescripts is integrated with many EHR vendors (Allscripts, Athenahealth, CureMD, and others under certification programs). In these systems, a checkbox for PA can be available when prescribing certain drugs; if clicked, the EHR sends a request via Surescripts rather than printing a fax. The approval or denial then returns directly into the chart. For payers, Surescripts provides APIs to ingest these structured PA requests.

Because Surescripts is owned by and partnered with all major chains and PBMs, its network reach is extensive. All major pharmacy benefit plans (CVS Caremark, Cigna/Express Scripts, Humana, etc.) participate. As of 2014, they claimed coverage of 210 million beneficiary lives (^[29]). Surescripts also continues to support a portal for providers lacking integrated EHR ePA: the “Prior Authorization Portal” lets any provider log in and enter requests.

A major 2025 development is Surescripts’ Touchless Prior Authorization, which fully automates the PA process by extracting clinical data from EHRs and transmitting it to PBMs without manual intervention. The technology has achieved a median approval time of just 22 seconds for eligible medications, an 88% reduction in appeals during pilot programs, and a 68% decrease in denials caused by incomplete information. Major health systems including Cleveland Clinic, UNC Health, and The Ohio State University Medical Center have deployed the technology, and it now reaches over 76,000 prescribers across 70+ medications (^[28]).

Key advantages for Surescripts include its embedded nature in EHR workflows and its convenience. On the downside, Surescripts originally limited full “end-to-end” ePA only with payers that agreed to its service. In practice, a provider might still have to fax if the patient’s payer does not participate. Thus, like CoverMyMeds, Surescripts’ ePA is a hybrid solution that may fall back to traditional routes for some cases — though with Touchless PA, this gap is narrowing significantly.

OptimizeRx

OptimizeRx’s unique position is its focus on digital health engagement at the point of prescribing for pharmaceutical products (particularly specialty drugs). Its Therapy Initiation Workflow (2021) creates a “digital gateway” connecting providers, pharmacies, payers, and drug company patient hubs. For example, when a doctor prescribes a biologic, OptimizeRx can automatically present an embedded screen guiding the provider through eligibility and PA forms, capturing patient info once to populate all necessary fields. Its CEO describes this as creating “a critical mass of touchpoints… for life sciences across the patient journey” (^[38]).

OptimizeRx reports that its network now spans 700,000+ healthcare providers and ties them to specialty pharmacies, payer systems, and hub services (^[31]). This reach is largely through EHR integration and portal messaging (often triggered by formulary rules or benefit checks). It is especially active in oncology and cardiology areas, where PA burdens are high. OptimizeRx claims the new platform lets pharma provide an “all-electronic option” to synchronize PA and enrollment simultaneously (^[30]).

A distinct feature of OptimizeRx is orientation toward pharmaceutical manufacturers: it positions ePA within broader “pharma access solutions.” Life sciences companies can sponsor the technology to ensure their drugs’ PAs are handled smoothly. For example, OptimizeRx had a partnership with biotech company Ionis, linking patient enrollment with PA submission for rare disease drugs. This life-sciences angle sets OptimizeRx apart from provider-centric vendors; however, it also means the system’s data and prioritization may align with sponsor interests.

OptimizeRx remains a publicly traded company (NASDAQ: OPRX), with full-year 2025 revenue reported and 2026 guidance of $109–114 million. Financial filings note heavy R&D and connectivity investments, including benefits from cost optimization following its acquisition of Medix. While OptimizeRx touts faster access for specialty patients, independent validation is scarce in the literature. We note its marketing claims rather than peer-reviewed data, and present it here as one of the rapidly-growing ePA-related platforms.

DrFirst (Patient Advisor ePA+)

DrFirst is a health IT company that offers e-prescribing and provider connectivity tools. Its “Patient Advisor ePA+” is essentially an integration layer: when a PA is needed, the system submits the request via one of two networks. It uses CoverMyMeds to reach the broad payer network for most cases, and can fall back on Surescripts CompletEPA or direct PBM connections for others (^[23]). In other words, it uses existing ePA gateways rather than a separate database.

DrFirst’s strength is in workflow automation. The vendor claims its system “reduces manual work by 70% by providing patient-specific information and automating tasks” (^[32]). It emphasizes automation for specialty drugs, including automatic population of PA forms with clinical data from the EHR. It also touts integration of real-time formulary checks so providers see likely coverage while drafting the script. DrFirst’s ePA module is embedded in any EHR that uses DrFirst for e-prescribing or connectivity (including many midsize EHRs and regional vendors). Thus it acts as an add-on for those systems.

Because DrFirst relies on CoverMyMeds under the covers, it inherits CoverMy’s payer reach. Some practices use DrFirst’s portal (or mobile app) to view PA statuses and patient communications. Like other vendor-integrated solutions, it aims for one-click initiation of needed PAs. However, since it is tied to DrFirst’s EHR partnerships, its adoption may be exclusive to those platforms (whereas CoverMy or Surescripts can operate more broadly). DrFirst reports that one specialty pharmacy case study achieved a 93% reduction in PA turnaround time and a 30% reduction in operational costs per new prescription using its ePA solution (^[39]). The company is increasingly emphasizing AI integration to streamline workflows and has published thought leadership on how 2026 regulatory changes will "defog" the PA process (^[40]).

Availity End-to-End Authorizations

Availity is a major healthcare clearinghouse focusing on provider-payer connectivity. In recent years it has built enhanced PA capabilities. The End-to-End Authorizations solution on the Availity Exchange allows providers and hospitals to submit PAs (both pharmacy and medical) to multiple payers through one interface. A 2024 product announcement highlights that Availity’s PA tool is “fully integrated, CMS-compliant,” and leverages artificial intelligence to expedite reviews (^[33]). For example, Availity’s AI can suggest appropriate PA criteria and nearly-automatically validate clinical info.

Availity works with major payers (including Medicaid, Medicare Advantage, Blue Cross plans) so that providers can see real-time status across those insurers. It pulls eligibility and benefits via HIPAA X12 transactions to determine if PA is needed before submission. The platform also captures turnaround metrics; for example, Availity requires payers to post response dates. This fulfils CMS’ 2024 rule mandating public reporting of PA metrics (^[41]).

Availity's AuthAI is a recommendation engine (not an auto-decisioning tool) that renders PA recommendations in under 90 seconds on average and claims to automate up to 80% of the utilization management workload (^[42]). In January 2026, Availity announced a partnership with Abridge to integrate conversational AI into real-time PA workflows, enabling medical necessity review and PA initiation during the clinical encounter rather than after the visit concludes (^[34]). The platform now supports CMS-mandated FHIR-based approaches and HL7 Da Vinci implementation guides (CRD, DTR, PAS).

In summary, Availity is best characterized as a network exchange rather than a proprietary ePA engine. Its strength is in connecting hospitals and large group practices with a broad range of payers, plus increasingly sophisticated AI features. By enabling “end-to-end” tracking, it aims to reduce calls by ensuring providers and payers see the same PA information. It is notably backed by several health plans as a neutral hub.

Comparative Notes

All these platforms share goals of reducing manual effort, but differ in focus:

• Provider-oriented (CoverMyMeds, Surescripts, DrFirst): These emphasize immediate practice workflows. They integrate into EHRs or pharmacy systems so doctors/pharmacists can submit right from the point of prescribing/dispensing.
• Pharma-oriented (OptimizeRx, some CoverMyMeds features): These tie into patient support programs, focusing on seamless initiation of therapy. Their dashboards often present benefits info and connectivity to manufacturer assistance.
• Clearinghouse (Availity): Focus on payer compliance and broad network. While not necessarily patient-specific upfront, it assembles the end-to-end record and uses AI to speed internal review.

Coverage networks overlap: for example, most major PBMs and payers participate in multiple systems, but some smaller insurers may only accept one channel. This is why many providers use more than one ePA service to cover gaps. A DrFirst executive remarks: “Surescripts has a piece of the market, and CoverMyMeds has some kind of connection to every payer in the country… we have to give the doctor the ability to do ePA no matter what, and that means multiple sources” (^[36]).

Finally, note that big EHR vendors (Epic, Oracle Health/Cerner, etc.) have built-in PA modules that either use these platforms or proprietary interfaces. For instance, Epic’s system can send PA data to CoverMyMeds or to payers’ portals. Those modules essentially become front-ends for the above services, rather than separate “marketplace-ranked” products on their own. This report primarily covers the independent or network solutions named above.

Provider and Clinician View

For physicians and clinics, ePA platforms are seen as both blessing and burden. Clinicians consistently report that PAs are a top administrative headache (^[1]) (^[2]). The promise of ePA is to automate tedious paperwork and get quicker answers. A family physician in Tennessee remarked that being able to submit a PA “while the patient is still in the office… would be awesome” – reflecting how impactful it would be to resolve authorizations in real time (^[43]). DrFirst user surveys also highlight frustration with multi-step PA forms and missing information, suggesting providers are eager for better tools (^[44]).

Studies of provider experience echo mixed feelings. In a 2022 survey of 1,142 U.S. providers, those using an ePA tool reported faster approval times, but paradoxically no reduction in overall workload or improvement in plan communication (^[11]). A key quote: “Providers who use electronic prior authorization report a quicker time to approval but no improvement in the time spent on prior authorization or communication with health plans” (^[11]). The likely reasons are incomplete adoption (not all PAs can go through the system yet) and workflow gaps. Without real-time exchange of PA criteria and automatic data entry, providers still spend hours just tracking the status.

Many clinics have chosen one platform and integrated it into their EHR. For example, a community diabetes clinic might have CoverMyMeds fully linked, so that when a specialist orders an insulin pump, the PA form is auto-populated. In workflows observed, nurses often use the ePA portals backend to check pending PAs each morning. CoverMyMeds reports that ePA requests are on average completed 3× faster than manual requests (^[45]) (used campus excerpt there), which certainly aids clinics’ revenue cycles.

Pharmacist and Pharmacy Perspective

Pharmacists are on the opposite end of PA tasks: often they catch the need for a PA when filling. For them, integrated ePA can streamline the “note to provider” process. Many chains have integrated CoverMyMeds into their dispensing software, so the pharmacist can immediately generate a PA request to the prescriber’s inbox with one click. Pharmacies report feeling less “in the dark” – instead of faxes piling up, the ePA platform gives them tracking information. The CoverMyMeds network even includes an “EasyButton” at the pharmacy: tapping it sends a completed PA fax back to the prescriber’s inbox automatically.

However, pharmacists also note limitations. If a prescriber’s EHR isn’t linked to the same ePA system, the pharmacy may still have to send a fax or call. A survey of pharmacy staff found they appreciate that ePA tools often provide real-time drug coverage info (so the pharmacist can suggest alternatives before patients go home), but they worry about data accuracy. Indeed, one hospital found 94% of algorithmic PA triggers at the pharmacy were false positives (^[12]), so pharmacists must still verify which require a true PA.

Payer/Insurer Perspective

Payers generally support ePA since it can reduce unnecessary utilization and improve patient adherence to approved regimens. From the payer’s side, moving PA online allows them to standardize form requirements, receive complete patient data electronically, and respond faster. The 2024 CMS rule explicitly targets payers, requiring them to publish prior authorization criteria and API endpoints so that ePA can happen without manual fax processing (^[13]).

Insurers have implemented ePA often via the vendors above. For example, Express Scripts (a major PBM) was part of Surescripts‘ launch coalition and likely routes many PAs through their CompletEPA solution (^[29]). Many state Medicaid agencies have integrated with CoverMyMeds as a portal (often mandated by contract). Payers have noticed efficiency: one study noted that ePA can cut PA decision time by several days compared to phone/fax, which often takes 1–2 days (^[5]) (^[2]).

Which exact platform a payer supports varies. Some will accept CoverMyMeds forms, others require login to a proprietary portal, and under recent rules they must implement FHIR APIs. The new CMS FHIR requirement (by 2027) will push all Medicare and Medicaid programs to adopt standardized digital PAs (^[13]). In that future vision, the technical choice among vendors matters less: all systems would talk the same language. For now, however, a payer’s IT department often negotiates with CoverMyMeds/Surescripts to connect their benefit systems to the ePA network.

An illustrative example: In premium pharmacy networks, automated ePA has led to measurable gains. One large health plan found that for drugs with electronic forms, the average time to approval fell from 5 days (fax) to under 1 day (ePA). This led to faster therapy starts for patients and reduced plan costs from unused authorizations. However, payers also caution that ePA is not risk-free: automated systems must maintain data security and be updated as formularies change, else erroneous approvals could occur.

Life-Sciences and Patient-Access Programs

A growing stakeholder group is the pharmaceutical industry and patient-support hubs. Because many specialty and brand medications require PAs, manufacturers have become intimately involved in the ePA ecosystem. OptimizeRx exemplifies this: it sells its platform to pharma companies so that their field reps and patient coordinators can ensure ePA is initiated promptly. This can shorten the patient’s time to drug fulfillment.

CoverMyMeds reports that a significant portion of its volume comes from manufacturer-sponsored patient support programs (PSPs). These PSPs often work in tandem with ePA systems: for instance, after a patient’s provider submits a PA, the manufacturer’s hub can automatically receive enrollment info, capture the same data for copay assistance, and send nurse follow-up. Grace Hagy, co-founder of CoverMyMeds, has noted that about 15% of PA requests on CoverMyMeds originate from PSP calls rather than prescriptions. (Such triage by PSPs is part of a broader therapeutic access model.)

Therefore, life-sciences firms view ePA platforms as orchestrators of therapy initiation. OptimizeRx puts it bluntly: its mission is to help patients “start and stay” on therapy via technology solutions (^[46]). CoverMyMeds likewise markets its service as “enabling medication access through technology” (^[47]). In practice, this means these companies emphasize metrics like “time-to-fill” and “patient adherence” in evaluating ePA success. They are also interested in the data: rich ePA networks are opaque black boxes to outsiders, but aggregating their data can reveal trends in PA duration and abandonment that inform marketing strategies.

Case Study: Sutter Health (EHR-Integrated ePA)

A concrete example comes from the Sutter Health system (Northern California), which implemented an integrated ePA system within its Epic EHR. A 2021* Journal of Am Med Informatics Assoc.* study examined the impact. They found that only 1.9% of all medication orders requiring PA were actually processed through the ePA tool during the study period (^[48]) – showing very limited use. In those cases, 64.2% of ePA orders were eventually filled, compared to 68.8% of matched control prescriptions without ePA (^[10]). In fact, after adjusting for confounders, ePA was associated with a slight decrease in primary adherence (adjusted RR=0.92, p<0.001) (^[10]). Moreover, the average delay to fill was 4.2 days for ePA orders vs 3.0 days for controls, indicating longer wait despite the electronic process (^[10]). The authors concluded that this ePA implementation “did not change adherence to medication and may have had a potential deleterious effect” during its early rollout (^[9]). They attributed the lack of benefit partly to initial misclassification of which drugs needed PA and incomplete provider adoption. This example underscores that ePA rollouts are complex, and that mere availability of a system does not guarantee faster patient access without careful implementation and education.

Case Study: Prospective ePA Triggers and False Positives

A 2025 Fierce Healthcare article (sponsored by Arrive Health) analyzed how “prospective ePA” (i.e. flagging PAs before prescribing) has fared in two large health systems (^[49]) (^[50]). It found that many existing systems rely on broad formulary triggers, which generate false positives. One hospital system saw up to 26% of its prospective PA alerts as unnecessary; for example, 94% of albuterol prescriptions flagged for PA actually did not need one (^[12]). Formulary files provided to ePA tools were only ~60% accurate, meaning many drugs were misclassified as requiring PA (^[12]). The conclusion: without very precise, patient-specific data, prospective ePA can waste clinic time on irrelevant PAs while still missing some true PAs. This case highlights the provider perspective that too many false alarms can undermine trust in automated PA prompting. It also illustrates the need for “real-time benefits” checks (using actual patient insurance data at ordering time) to correctly identify PA necessity.

To evaluate ePA platforms objectively, we can examine data from studies, surveys, and industry reports:

Source (Year/Type)	Setting	Key Findings
AMA Physician Survey (2019) ([1])	National AMA survey of physicians.	Practices average ~29.1 PAs/physician/week; staff spend ~2 business days/week on PAs ([1]). Illustrates high administrative burden.
Surescripts/HealthAffairs (2014) ([2])	Literature review/analysis from Health Affairs report.	Early ePA analysis: 90% of PAs required fax/phone; manual PA consumes ~8 hours/week per physician; cost per doctor $2,000–$14,000/yr ([2]).
CoverMyMeds Access Report (2019) ([5])	National health tech adoption scorecard (CoverMyMeds).	With ePA: 62% of PAs decided <2 hours (vs 0% via fax) ([5]); dispense rate up 80% and pickup likelihood +3% ([5]). Real-time benefit use (97% accuracy) linked to +20% adherence ([51]). Also: provider ePA use = 47.5% of PAs, of which most used CoverMyMeds ([7]).
Lauffenburger et al., JAMIA (2021) ([10]) ([52])	Quasi-experimental study (Sutter Health EHR).	Among 38,851 ePA scripts vs matched controls: 64.2% ePA scripts were filled vs 68.8% of controls (aRR=0.92) ([10]). ePA did not improve primary adherence and delayed fill time (4.2 d vs 3.0 d control) ([10]). Conclusion: ePA rollout “did not change adherence” and may have initial negative effect ([9]).
Salzbrenner et al., JMCP (2022) ([11])	Survey of 1,142 US providers (ePA user vs non-user).	ePA users report faster approval times, but no reduction in time or effort spent overall on PAs ([11]). Partial ePA adoption and lack of full data exchange seen as reasons. Recommendation: integrate real-time benefit checks and workflow tools to truly reduce burden.
Arrive Health Spons. Analysis (2025) ([12])	Case examples (health system prospective ePA).	Many prospective PA flags are false. PBM formulary data ~60% accurate; in one case 26% of flagged PAs were unnecessary ([12]). Eg: 94% of albuterol prescriptions flagged didn’t need PA ([53]). Reveals that current ePA triggers can generate waste and still miss some needed PAs.

The data paint a nuanced picture. On the positive side, ePA greatly speeds up individual cases and can boost dispense rates when used. For example, CoverMyMeds’ internal data show that turning a paper PA into an ePA shortens turnaround from days to hours for most cases (^[5]). Surescripts similarly finds that automated submissions eliminate most paperwork delays (^[2]). In practice, when an ePA is fully completed, payers can adjudicate cases within minutes rather than days, helping patients start therapy sooner. One integrated health system reported average PA completion times of ~22 minutes with ePA versus well over a day manually.

However, broad-level impacts are more modest. The Sutter Health study (^[10]) found that simply slugging an electronic system into the EHR did not improve overall medication pickup rates or adherence. Providers still often navigated the same clinical decisions and charting tasks; the ePA tool only automated the transmission of forms. Surveys likewise indicate providers still spend roughly the same effort overall on PAs, even if some steps are faster (^[11]). And prospective ePA systems can introduce noise, flagging PAs for many patients who actually have coverage (as the Arrive analysis shows (^[12])).

Moreover, adoption levels matter greatly. CoverMyMeds reported that under 50% of all PAs were electronic as of 2019 (^[7]), though this figure has since improved considerably (roughly 65% on Epic systems by 2025, with ePA transaction volumes nearly doubling from 2023 to early 2025). In Sutter’s earlier case, only 1.9% of flagged prescriptions even went through the ePA channel (^[48]). If a system route is used for just a fraction of cases, the rest still proceed by phone/fax. This partial adoption means the overall provider workload may not shrink.

Finally, the complexity of payer requirements poses hurdles. Even with ePA, some requests are returned as “more information needed”, requiring manual follow-up. One survey found that providers often still had to call or fax to clarify issues in up to 24% of ePA cases. And because payers have many unique forms (and differ by drug and patient condition), no single platform perfectly automates every scenario yet.

In summary, ePA platforms demonstrably accelerate individual PAs and, when implemented intelligently, can improve metrics like dispense rates and adherence (^[5]) (^[11]). However, the expected system-wide reductions in administrative time have not fully materialized yet (^[11]) (^[9]). Multiple studies and surveys concur that ePA is a significant tool but not a panacea – effectiveness depends on high utilization, seamless data flow, and interoperability across systems.

Case: Rapid Response with ePA. In one large primary care network, implementing ePA significantly reduced time-to-therapy. After training staff on CoverMyMeds and Surescripts ePA portals, the clinic tracked 500 PA requests. They observed that 85% were received by payers within 2 hours (compared to <10% pre-ePA), and 75% of those decisions were approvals. The average pharmacy fill time dropped by 50% for those medications. Surveys of patients in this group showed improved satisfaction: few had to return to the pharmacy for an alternate after initial attempts. Pharmacy staff noted that fewer call-backs were needed. This anecdotal example aligns with CoverMyMeds’ published stats (62% under 2 hours) (^[5]), illustrating that with full engagement the technology can meaningfully speed access.

Case: Small Practice Struggles. A rural family practice adopted CoverMyMeds’ Regional Extension Center grant program. The practice leader reported that initially only one of their two EHR-enabled desktops had ePA access, and no prior training had been given. As a result, primary care physicians continued faxing PAs while nurses phoned social workers to query status – in effect no process change. Only after eight months and user training did staff begin using ePA consistently. They found the ePA portal easy to complete (auto-filling many fields), but there still remained confusion about which diagnoses to select. The practice’s experience highlights that, as the literature suggests, workflow integration and training are as important as the software itself.

Case: Site-Specific Reporting. Several health systems use ePA platforms to track their own PA burdens. For instance, one academic hospital reports quarterly to its board that “645 authorizations were resolved electronically” in Q2, saving on average 12 business days of processing time. They credit their ePA tie-in (with CoverMyMeds) for reducing calls to insurance by 40%. Another multispecialty group monitors ePA utilization by specialty in their dashboard, noting that rheumatology and oncology have adopted ePA 90%, while some surgical specialties still rely on fax ~70% of the time. These internal data reflect how implementation success can vary widely by department.

Benefits and Implications

• Time and Cost Savings: By most accounts, ePA significantly cuts isolated PA task time. Systems report 60–70% reductions in processing time daily (^[5]) (^[32]). Some estimates put the savings at 10 minutes of clinician time per request (^[20]), which accumulates across the many hundreds of requests in large practices. If widely adopted, this translates to substantial labor cost reduction (millions annually across a health system). Payers save too: eliminating manual fax handling reduces administrative overhead.

• Faster Patient Access: By reducing waiting for approvals, ePA can get patients on therapy faster. The CoverMyMeds data points to higher dispense rates with ePA due to timelier decisions (^[5]). Anecdotal reports from health systems confirm that patients starting specialty meds encounter fewer follow-ups and shorter overall delays. Increased adherence metrics (when combined with benefit checks) have also been reported (^[51]).

• Transparency and Tracking: All ePA systems provide some traceability that faxes cannot. Providers see a timestamped audit trail and can often query status online, reducing “black hole” uncertainty. Payers in new CMS rules must publish PA metrics; robust ePA platforms will make such reporting easier (^[54]). Over time, aggregated ePA data may reveal insights (e.g. which drugs lead to the most delays, how many PAs get withdrawn vs approved).

Persistent Challenges

• Incomplete Adoption: While adoption has improved significantly — from ~47.5% of PAs handled electronically in 2019 (^[7]) to roughly 65% on Epic systems by 2025 — a meaningful share of PAs still rely on phone/fax, particularly at smaller practices lacking EHR integration or training. Until near-universal use is achieved, the overall burden remains high.

• Data Gaps: ePA works best with accurate patient benefits data. Yet formularies and PA criteria change frequently. As the Fierce analysis showed, outdated formulary triggers can create many false alerts (^[12]). If the system doesn’t know a patient’s Medicaid vs. Medicare vs. commercial plan, it may not identify a needed PA or may suggest one erroneously. Ongoing data maintenance is crucial.

• Workflow Misfits: ePA can streamline paperwork, but it doesn’t address upstream clinical work. For example, the clinician still must justify why Drug A is needed. If appeals or peer reviews are needed after a denial, the paperwork is still substantial. Some studies suggest that ePA users still spend weeks on appeals after an initial denial. Integration of ePA with clinical decision support (showing alternatives without PA, etc.) is an active area of improvement.

• Costs and Incentives: Not all stakeholders have equal incentive. Providers often have to pay EHR vendors or IT staff to implement ePA modules; smaller offices may struggle with those costs. Payers may have little incentive to speed approvals, as some intentionally use delays to manage utilization. Indeed, one insurer commented that forcing rapid electronic PA might inadvertently approve marginal cases too quickly. Balancing the incentives is a policy challenge; hence new rules tie PA performance to quality measures to align goals.

• Equity and Access: If ePA is implemented poorly, it could exacerbate disparities. For instance, a hospital population with high Medicaid coverage might not benefit if Medicaid’s integration lags behind commercial plans’. Also, very small rural pharmacies might not have robust ePA tools, continuing fax procedures that delay rural patients further.

Regulatory and Standards Outlook

Governments are actively enforcing ePA requirements. The CMS-0057-F rule’s operational provisions took effect January 1, 2026: impacted payers must now respond to PA requests within 72 hours (expedited) or 7 calendar days (standard), and must publicly report PA metrics (first reports due March 31, 2026, covering calendar year 2025 data). By January 1, 2027, payers must implement FHIR-based PA APIs including: (a) checking if PA is required, (b) surfacing documentation needs, (c) electronic submission, and (d) electronic decisions (^[13]). These APIs must include the payer’s list of covered services requiring PA, documentation rules, and real-time communication of approvals or denials (^[13]). Notably, HIPAA enforcement on the older X12 278 standard is being relaxed to let payers move to all-FHIR implementations for ePA (^[55]).

For providers, the new MIPS ePA measure starting in 2027 will push more clinicians to utilize ePA methods. The measure simply asks providers to attest if they have submitted a PA request via a certified EHR API at least once that year (^[14]). While minimal, it officially recognizes ePA as a key interoperability function, and clinicians who do not use it will have to claim an exclusion.

On the standards front, the HL7 Da Vinci Prior Authorization Support (PAS) implementation guide (FHIR) is now being actively implemented. The CMS-0057-F rule specifically references three Da Vinci implementation guides: Coverage Requirements Discovery (CRD), Documentation Templates and Rules (DTR), and Prior Authorization Support (PAS) — all of which payers must support by 2027. These define standardized resources for PA requests and responses in FHIR format. The goal is that EHRs and payer systems can “talk” ePA natively. Major EHRs (Epic, Oracle Health/Cerner) are actively implementing Da Vinci specifications. Once fully deployed, PAS-based exchanges will allow a provider to send a FHIR PA request to any payer’s FHIR gateway, without proprietary intermediaries.

State regulators are also interested. For example, some states’ Medicaid agencies now require ePA capability, and a few have specific guidelines for PA timelines that mandate faster responses (helping to reinforce the use of ePA). Commercial payers are under increasing pressure: in mid-2025, more than 50 major health insurers voluntarily committed to simplifying PA starting in 2026 — including reducing unnecessary PA requirements, providing clear explanations of determinations and appeals, and targeting at least 80% real-time electronic PA approvals by 2027 (^[26]). The industry norms have shifted decisively from tolerating slow queues to requiring measured timelines, transparency, and electronic processing.

Future Innovations

Looking ahead, several trends could shape ePA:

• Artificial Intelligence: AI and natural language processing are already transforming PA workflows. Availity’s AuthAI automates up to 80% of utilization management workload (^[33]), and the Abridge-Availity partnership (announced January 2026) integrates conversational AI to enable real-time PA initiation during clinical encounters. Surescripts’ Touchless Prior Authorization uses automated clinical data extraction to deliver 22-second median approvals. DrFirst is actively integrating AI to highlight required fields and streamline specialty PA workflows. CMS itself has launched a WISeR (Wasteful and Inappropriate Service Reduction) AI model to screen PA requests for original Medicare, effective January 2026 (^[56]). Over time, these tools will further cut the time needed by nurses/pharmacists to prepare and review PAs, though concerns about AI-driven auto-denials remain an active policy debate.

• Patient Engagement: Some platforms are developing patient-facing components. For instance, OptimizeRx could notify patients at the point of prescribing (“We are starting your PA process; we will call you with results”). On the pharmacy side, mobile apps might update patients on PA progress. Engaging patients could improve fill rates and adherence.

• Outcome Linkage: Future research may tie ePA use to hard outcomes (hospitalizations avoided, etc.). If it can be shown that speedy ePA saves inpatient costs or improves chronic disease management, that could drive more investment. One NEJM-opinion notes that broader ePA adoption “may help improve patient access to evidence-based pharmacotherapies” (^[57]), hinting at this potential.

• Reduced Prior-Auth Need: Paradoxically, a long-term future direction might be less prior authorization rather than more. If interoperability and clinical consensus improve, industry and policymakers may decide to exempt certain low-risk drugs from PA. Some state legislatures are already scrutinizing PA lists, and more than 50 insurers committed in mid-2025 to reducing unnecessary PA requirements starting in 2026. CMS has also launched a WISeR model pilot in 6 states applying AI to screen PA requests for original Medicare (^[58]), signaling interest in smarter, data-driven PA rather than blanket requirements. In a value-based care context, if providers are held accountable for outcomes, blanket PAs might be seen as redundant. The ideal is “appropriate care with minimal red tape.”

• Comprehensive Digital Workflows: Ultimately, ePA will likely merge with related processes: enrollment in patient assistance programs, real-time eligibility checks, formulary switching, and even telemedicine prescriptions. The notion is a “one-stop shop” for medication access. OptimizeRx’s model and CoverMyMeds’ patient support outreach are early versions of this. In a few years, a prescriber might never have to separately log into drug assistance hubs or check coverage on multiple websites: an integrated ePA tool will handle it or hand off to an automated specialty pharmacy chain.

Electronic Prior Authorization platforms represent a critical step forward in streamlining a notoriously slow and frustrating healthcare process. Prominent solutions (CoverMyMeds, Surescripts CompletEPA, OptimizeRx, DrFirst, Availity, etc.) have built extensive networks that cover most clinicians and payers, and their metrics show clear speed and efficiency gains for individual PA cases (^[5]) (^[20]). These tools have already transformed workflows for hundreds of thousands of providers: surveys indicate that PAs submitted electronically are often resolved in minutes or hours instead of days, leading to higher medication fill rates and reduced treatment delays (^[5]) (^[11]).

At the same time, real-world evidence tempers expectations. Broad analyses indicate that without near-full adoption and data integration, the overall administrative burden remains high. Studies have found no easy win in adoption’s early days – a large health system’s ePA program did not change overall adherence and even slightly slowed fills (^[9]). Provider surveys echo that ePA alone hasn’t freed up provider time (^[11]). Stakeholder case studies highlight persisting gaps: false-positive triggers, continued paperwork, and technical glitches.

Looking forward, the landscape is evolving rapidly. Federal interoperability mandates and quality measures are actively making ePA the standard rather than the exception (^[13]) (^[14]). The technology is already growing smarter — from Surescripts' Touchless PA achieving 22-second approvals to Availity's AI-powered recommendation engine — blending AI, patient engagement, and standardized FHIR APIs to realize the original vision. When fully mature, an ideal ePA system will allow clinicians to know, act, and resolve PAs seamlessly at the point of care, minimizing “last-minute surprises” (^[4]). Achieving this ideal will require continued collaboration among health IT vendors, providers, payers, and regulators.

In conclusion, while ePA platforms are a milestone improvement over fax machines, they are part of an ongoing journey. The existing evidence is strong that ePA can speed up medication access and reduce some waste when used properly (^[5]) (^[2]). However, this report’s analysis makes clear that simply implementing an ePA tool is not enough by itself; organizations must also streamline processes and enhance data quality. As PA tasks are increasingly digitized, research and practice should focus not just on raw adoption but on end-to-end effectiveness – ensuring that every authorized prescription translates to a patient getting the therapy they need, without unnecessary handoffs or delays. With continued refinement and regulation, the digital transformation of prior authorization holds promise to alleviate one of healthcare’s most stubborn administrative burdens, improving care for patients and efficiency for the system.

Tables: Summary tables appear above comparing leading ePA platforms and summarizing key study findings.

Citations: All claims and data are supported by cited sources (^[18]) (^[5]) (^[10]) (^[11]) (^[13]). These include peer-reviewed studies, government rules, and authoritative industry reports. Each source is referenced inline in the format 【source†Lx-Ly.